LONA
LeonaBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.56
−1.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 68.6M | 68.1M | — | — | — |
| Gross Profit | (68.6M) | (68.1M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 33.3M | 17.5M | 70.7M | 93.8M | 61.5M |
| SG&A Expense | 21.3M | 16.7M | 26.1M | 33.3M | 32.6M |
| General & Admin Expense | 21.3M | 16.7M | 26.1M | 33.3M | 32.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (56.0K) | — | 4.1M | (1.6M) | 10.0M |
| Total Operating Expenses | 54.5M | 34.2M | 100.9M | 125.5M | 104.0M |
| Cost and Expenses | 123.0M | 102.3M | 100.9M | 125.5M | 104.0M |
| Operating Income (EBIT) | (123.0M) | (102.3M) | (100.9M) | (125.5M) | (104.0M) |
| Non-Operating | |||||
| Interest Income | 1.3M | — | 4.0M | 7.6M | 3.2M |
| Interest Expense | — | — | — | — | 24.3M |
| Net Interest Income | 1.3M | — | 4.0M | 7.6M | (21.1M) |
| Other Non-Op Income/Expense | (18.4M) | (3.3M) | 4.0M | 7.8M | 8.4M |
| Non-Operating Income (excl Interest) | (68.8M) | (68.1M) | (4.1M) | 1.5M | (15.2M) |
| EBT (Pre-Tax Income) | (141.5M) | (105.6M) | (96.9M) | (117.7M) | (95.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (141.5M) | (105.6M) | (96.9M) | (117.7M) | (95.6M) |
| Earnings from Cont. Ops | (141.5M) | (105.6M) | (96.9M) | (117.7M) | (95.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (141.5M) | (105.6M) | (96.9M) | (117.7M) | (95.6M) |
| Per Share | |||||
| Basic EPS | ($32.78) | ($24.70) | ($25.20) | ($30.90) | ($25.30) |
| Diluted EPS | ($32.78) | ($24.70) | ($25.20) | ($30.90) | ($25.30) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.3M | 4.3M | 3.8M | 3.8M | 3.8M |
| Diluted Shares Outstanding | 4.3M | 4.3M | 3.8M | 3.8M | 3.8M |
| Profitability Metrics | |||||
| EBITDA | (53.7M) | (33.2M) | (95.8M) | (126.0M) | (88.0M) |
| D&A | 582.0K | 972.0K | 970.0K | 969.0K | 845.0K |
| EBIT | (54.2M) | (34.2M) | (96.8M) | (126.9M) | (88.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026